AI 채팅
Loading data for NXTS — first visit, this takes a few seconds.

Nexentis Technologies Inc.

NXTS · NasdaqCM · USD

1.56 -0.06 (-3.70%)

종가 기준: Sep 15, 2026, 8:00 PM

거래량
7.98K

Nexentis Technologies Inc.(NXTS) 주가, 분석 및 데이터

내재가치

내재 가치 로딩 중…

애널리스트 전망

주가 전망 →

애널리스트 전망 없음

12개월 목표가 · 애널리스트 n/a명

애널리스트 컨센서스: n/a

간격:1D
캔들과 신호 불러오는 중…

재무 실적

재무 정보 보기 →

불러오는 중...

최근 실적

발표치예상 대비전년 대비
매출n/an/a
EPSn/an/a

다음 실적 발표

실적 상세 보기 →

지표

매수호가
1.16
순이익 (ttm)
-16.6M
1.87
7.48
0.19
n/a
P/B (ttm)
1.09
P/S (ttm)
n/a
실적 발표일
n/a
매도호가
2.07
거래량
7,980
평균 거래량 (20일)
1,298,831
시가
1.61
전일 종가
1.62
일중 범위
1.56 - 1.61
52주 범위
1.43 - 52.67
배당
n/a
배당락일
n/a

Nexentis Technologies Inc. 소개

기업 정보 보기 →
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel. Agricultural Inputs · Basic Materials

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

IPO 일자 Nov 12, 2010
직원 수 7
상장 거래소 NasdaqCM
티커 NXTS